A multicentre, observational, prospective analysing humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines in hemodialysis patients
Latest Information Update: 20 Oct 2021
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 20 Oct 2021 New trial record
- 01 Oct 2021 Primary endpoint has been met. (qualitative humoral and cellular responses to the mRNA vaccine), as per Results published in the American Journal of Kidney Diseases
- 01 Oct 2021 Results published in the American Journal of Kidney Diseases